32 results about "Liver cell cancer" patented technology

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast Cancer, lung Cancer, gastric Cancer, ovarian Cancer, hepatocellular Cancer, colon Cancer, pancreatic Cancer, esophageal Cancer, head & neck Cancer, kidney Cancer, in particular renal cell Carcinoma, prostate Cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid Cancer, and the metastatic forms thereof. In one embodiment, the rumor disease is metastatic cancer in the lung.

The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.

An oncolytic virus is for use in a method of treating or preventing cutaneous squamous cell carcinoma (CSCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), advanced recurrent head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), anal cancer, colorectal cancer (CRC), basal cell carcinoma (BCC), Merkel cell carcinoma, appendiceal carcinoma, sarcoma of the skin, recurrent melanoma after surgery, advanced or metastatic urothelial carcinoma, liver metastases, microsatellite instability high cancer (MSI-H), mixed advanced solid tumors, virally caused cancer, locoregionally advanced cancer, pediatric cancer, cancer in patientswith no or minimal pre-existing anti-cancer immunity, cancer as first line therapy, cancer in previously treated patients, cancer in patients who have not received checkpoint blockade therapy, and / orcancer in patients who have received checkpoint blockade therapy, wherein the oncolytic virus is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panelof three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and / or at a lower dose in vitro than one or more of the other clinical isolates in the panel; comprises (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule or an immune stimulatory molecule-encoding gene; comprises (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene; and / or comprises a gene encoding a CTLA-4 inhibitor.

The invention provides application of delinearized ubiquitin enzyme family with sequence similarity 105, member B (FAM105B) in liver cancer diagnosis, treatment and prognosis judgment. Various technical detection finds that the FAM105B is highly expressed in a liver cancer cell line and liver cancer tissue, and high expression of the FAM105B is positively correlated with adverse clinical pathological characteristics of a hepatocellular carcinoma (HCC) patient, a poor postoperative overall survival rate and a poor tumor-free survival rate; it is proved that high expression of the FAM105B in theliver cancer tissue is an independent risk factor influencing long-term survival of liver cancer patients; an in-vitro hepatoma cell model constructed by gene knockout and overexpression techniques finds that the FAM105B can promote the proliferation, migration and invasion abilities and epithelial-mesenchymal transition of hepatoma cells. The research findings indicate that the delinearized ubiquitin enzyme FAM105B can be used as a marker for developing a new liver cancer diagnosis and prognosis judgment kit, and an effective target is provided for preparing liver cancer treatment medicines.

A hepatitis B virus antisense RNA expression vector targeted toward liver cancer is a gene therapeutic matter for hepatitis B virus related liver cell cancer. The present invention adopts EB virus expressing plasmid pEBAF as vector and positive liver cancer tissue expressing vector controlled by AFP promotor controlling and specifically expressed in AFP only to construct three kinds of HBV antisence RNA expression vectors pEBAF-as-preS2, pEBAF-as-preS1 and pEBAF-as-X, which contain HBV preS2, preS1 and X segment genes separately. Antisense RNA expression vector is prepared through amplifying a destination gene, designing, a primer, and a PCR amplification of HBpreS2, HBpreS1 and HBX genes. The antisense RNA expression vector is used for treating hepatitis B virus related liver cell cancer and hepatitis B virus infection.

The invention discloses the polymorphic site (rs4134994) in CDC6 gene associated with primary liver cell cancer and its application. The invention also provides a method for detecting the polymorphic site and susceptibility of the primary liver cell cancer. By use of the nucleic acid sequence of the polymorphic loci and its detection method, it can produce kit for preventing primary liver cell cancer and early diagnosis and treatment.

The present invention provides a kit for early screening of hepatocellular carcinoma, comprising a gene marker detection reagent and a protein marker detection reagent. The invention also provides a preparation method and application of the kit. The kit comprising specific gene markers and protein markers of the present invention has been demonstrated to be effective in achieving early screening of HCC in community populations, particularly in prospective studies.

The invention discloses the application of MINPP1 as a target molecule in the preparation of anti-HBV-related hepatocellular carcinoma drugs, and inhibits the growth and invasion of HBV-related hepatocellular carcinoma cells by overexpressing or activating the MINPP1 gene. The present invention confirms that the MINPP1 gene can be used as an important target for effectively inhibiting the proliferation of HBV-related liver cancer cells.

The invention discloses a reagent for detecting and targeting a lncRNA biomarker and application of the reagent to hepatocellular carcinoma. The up-regulated expression of CTD-2561J22.5 in a patient with liver cancer is discovered for the first time; and through ROC curve analysis on relevant data, the result that the CTD-2561J22.5 has the higher diagnosis efficiency is discovered. Cell experiments prove that through down-regulating of the expression level of the CTD-2561J22.5, the proliferation activity of liver cancer cells can be reduced; and the result shows that the CTD-2561J22.5 can be used as a molecular target to be applied to the treatment of the hepatocellular carcinoma.

The present invention relates to a nanobody of Glypican 3 with outstanding acid-base stability and a preparation method thereof, and also relates to the amino acid sequence of the nanobody, a gene coding sequence and an expression vector capable of expressing the nanobody and host cells. The amino acid sequence of the nanobody to GPC3 provided by the present invention is shown in SEQ ID NO:7, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO:8. The GPC3 nanobody involved in the present invention can specifically recognize liver cancer cells with high GPC3 expression by binding to the GPC3 expressed on the cell membrane. The antibody has outstanding acid-base stability, and can be used in the functional research of GPC3, and can also be used in the development of diagnostic reagents and therapeutic drugs for hepatocellular carcinoma.

The invention discloses a miRNA (micro ribonucleic acid) for diagnosis and treatment on hepatocellular carcinoma. The invention finds for a first time that expression of miR-4772-3p is decreased in liver cancer, and further verifies that miR-4772-3p has high diagnosis efficiency in liver cancer. The invention further discloses that miR-4772-3p plays significant roles in proliferation, migration and invasion of hepatoma carcinoma cells, and reminds that miR-4772-3p can be applied to treatment on liver cancer.

Provided are a liver cell cancer therapeutic agent, a therapeutic method, etc., which can exhibit more potent and sustained antitumor effects than a conventional multi-kinase inhibitor. The medicament is characterized by including, as a combination medicament for treating liver cell cancer: lenvatinib or a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof; and an antibody against human DLK-1 having an in-vivo anti-tumor activity or antibody fragments derived from said antibody.

The invention relates to the technical field of biomedicine, discloses an application of miR-6883-3p in preparation of an anti-liver cancer product or a liver cancer prognosis evaluation product, and particularly relates to an application of miR-6883-3p in preparation of an anti-liver cancer drug or a liver cancer prognosis evaluation kit. The miR-6883-3p targeted gene regulation network provided by the invention is closely related to malignant phenotype and poor prognosis of tumors, overexpression of miR-6883-3p can effectively inhibit proliferation and migration of liver cancer cells, promote apoptosis of the liver cancer cells and reverse the differentiation state of the liver cancer cells, and the miR-6883-3p is low in expression in liver cancer tissues, so that the miR-6883-3p can be used for preparing antitumor drugs or detection kits and has good application prospects.The method has potential application value in treatment or prognosis evaluation of hepatocellular carcinoma.

The invention relates to a serum CENPF antibody quantitative detection kit which can be used for specifically and quantitatively detecting the level of a CENPF antibody in a serum specimen. According to the serum CENPF antibody quantitative detection kit, recombinant CENPF antigen protein is coated in a 96-pore enzyme label board, the level of the CENPF antibody in the serum specimen can be quantitatively tested by using an enzyme linked immunosorbent assay, and the disease state of a liver cell cancer patient or high risk groups can be evaluated according to the level of the CENPF antibody in the serum. By adopting the serum CENPF antibody quantitative detection kit, a novel liver cell cancer screening and early diagnosis method is provided, and the sensitivity of the detected serum CENPF self-antibody is remarkably superior to that of a conventional clinical serum marker AFP when being used for diagnosing liver cell cancer.

The present invention relates to the use of a micromolecule RNA-30b-5p as a molecular target for resisting hepatitis B virus-related hepatocellular carcinoma. The invention discloses an application of miR-30b-5p as a target molecule in the preparation of anti-HBV-related hepatocellular carcinoma drugs. By inhibiting the transcription of miR-30b-5p or making it lose the function of binding to target genes, the growth and invasion of HBV-related liver cancer cells can be inhibited.

The invention selects the proteins with different expressions in cancer organization and cancer beside organism, to find one protein with high expression in cancer organization of liver cell cancer, wherein the immunity print test has proved that the 26S prolease adjustable subunit 1 (non ATP enzyme) has different expressions in cancer organism and cancer beside organism. Based on said relation, the protein can be used in protein molecule mark to detect liver cancer.